SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,960,417 | +20.2% | 263,657 | +13.5% | 0.01% | +42.9% |
| Q2 2023 | $26,599,518 | +9.2% | 232,270 | +31.4% | 0.01% | +16.7% |
| Q1 2023 | $24,359,730 | +19.0% | 176,737 | +11.9% | 0.01% | 0.0% |
| Q4 2022 | $20,468,715 | +48.2% | 157,962 | +26.4% | 0.01% | +50.0% |
| Q3 2022 | $13,815,000 | +83.9% | 124,990 | +24.7% | 0.00% | +100.0% |
| Q2 2022 | $7,512,000 | -24.9% | 100,206 | -21.8% | 0.00% | 0.0% |
| Q1 2022 | $10,004,000 | +64.1% | 128,081 | +89.1% | 0.00% | 0.0% |
| Q4 2021 | $6,098,000 | -28.8% | 67,720 | -26.9% | 0.00% | 0.0% |
| Q3 2021 | $8,563,000 | +41.5% | 92,593 | +18.9% | 0.00% | +100.0% |
| Q2 2021 | $6,053,000 | -30.8% | 77,856 | -33.6% | 0.00% | -50.0% |
| Q1 2021 | $8,741,000 | -92.5% | 117,280 | -84.7% | 0.00% | -92.9% |
| Q4 2020 | $116,360,000 | +40.8% | 767,128 | +28.3% | 0.03% | +21.7% |
| Q3 2020 | $82,666,000 | -6.4% | 597,690 | +8.5% | 0.02% | -11.5% |
| Q2 2020 | $88,355,000 | +85.4% | 551,042 | +13.1% | 0.03% | +62.5% |
| Q1 2020 | $47,645,000 | -27.5% | 487,057 | -4.3% | 0.02% | -11.1% |
| Q4 2019 | $65,699,000 | +77.1% | 509,153 | +3.4% | 0.02% | +63.6% |
| Q3 2019 | $37,104,000 | -64.2% | 492,600 | -31.2% | 0.01% | -62.1% |
| Q2 2019 | $103,705,000 | +37.0% | 716,408 | -3.9% | 0.03% | +26.1% |
| Q1 2019 | $75,717,000 | +11.2% | 745,845 | +19.5% | 0.02% | 0.0% |
| Q4 2018 | $68,099,000 | -21.0% | 624,008 | +16.9% | 0.02% | -4.2% |
| Q3 2018 | $86,231,000 | +83.1% | 533,900 | +49.8% | 0.02% | +71.4% |
| Q2 2018 | $47,105,000 | +0.9% | 356,372 | -44.6% | 0.01% | 0.0% |
| Q1 2018 | $46,697,000 | +192.1% | 643,848 | +119.6% | 0.01% | +180.0% |
| Q4 2017 | $15,985,000 | +17.1% | 293,146 | -4.4% | 0.01% | +25.0% |
| Q3 2017 | $13,655,000 | +273.4% | 306,741 | +182.8% | 0.00% | +300.0% |
| Q2 2017 | $3,657,000 | +45.8% | 108,477 | +28.1% | 0.00% | 0.0% |
| Q1 2017 | $2,508,000 | +34.3% | 84,710 | +24.4% | 0.00% | 0.0% |
| Q4 2016 | $1,868,000 | -19.9% | 68,090 | +79.2% | 0.00% | 0.0% |
| Q3 2016 | $2,333,000 | +230.5% | 37,997 | +2.7% | 0.00% | – |
| Q2 2016 | $706,000 | -2.1% | 37,008 | +0.1% | 0.00% | – |
| Q1 2016 | $721,000 | -53.9% | 36,957 | -8.9% | 0.00% | -100.0% |
| Q4 2015 | $1,564,000 | -67.6% | 40,575 | -73.0% | 0.00% | -50.0% |
| Q3 2015 | $4,831,000 | -43.8% | 150,457 | -46.8% | 0.00% | -33.3% |
| Q2 2015 | $8,601,000 | +9.3% | 282,637 | -52.3% | 0.00% | +50.0% |
| Q1 2015 | $7,870,000 | +96.3% | 592,636 | +105.3% | 0.00% | 0.0% |
| Q4 2014 | $4,009,000 | +418.6% | 288,623 | +686.8% | 0.00% | – |
| Q3 2014 | $773,000 | +3.8% | 36,683 | +46.6% | 0.00% | – |
| Q2 2014 | $745,000 | +60.2% | 25,027 | +29.3% | 0.00% | – |
| Q1 2014 | $465,000 | +9.4% | 19,356 | -7.3% | 0.00% | – |
| Q4 2013 | $425,000 | -87.5% | 20,871 | -71.0% | 0.00% | -100.0% |
| Q3 2013 | $3,405,000 | +4.1% | 72,090 | -16.2% | 0.00% | 0.0% |
| Q2 2013 | $3,272,000 | – | 86,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |